Cargando…

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy

Seroclearance of hepatitis B surface antigen (HBsAg) (“functional cure”) is the optimal endpoint of antiviral therapy for chronic hepatitis B virus (HBV) infection. Currently available anti-HBV therapy includes nucleoside/nucleotide analogs (NAs) and peginterferon-α (Peg-IFNα). Combination of NAs an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Kanako, Enomoto, Masaru, Tamori, Akihiro, Nishiguchi, Shuhei, Kawada, Norifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867160/ https://www.ncbi.nlm.nih.gov/pubmed/33535672 http://dx.doi.org/10.3390/ijms22031456

Ejemplares similares

The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B
por: Suoh, Maito, et al.
Publicado: (2020)

Recent Advances in Antiviral Therapy for Chronic Hepatitis C
por: Tamori, Akihiro, et al.
Publicado: (2016)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir
por: Tamai, Hideyuki, et al.
Publicado: (2017)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Hepatitis B virus infection and alcohol consumption
por: Iida-Ueno, Ayako, et al.
Publicado: (2017)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed
por: Nonomura, Ayami, et al.
Publicado: (2021)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Validation of a two‐step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis
por: Fujii, Hideki, et al.
Publicado: (2021)

Successful Transcatheter Arterial Embolization for Hemothorax from a Spontaneous Rupture of Hepatocellular Carcinoma Metastasis to the Chest Wall in an Elderly Patient
por: Suoh, Maito, et al.
Publicado: (2021)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
por: Kim, Jeong Han, et al.
Publicado: (2016)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
por: Jun, Dae Won, et al.
Publicado: (2018)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)

Risk factors for hepatocellular carcinoma in treated chronic hepatitis C patients–Relationship to smoking and alcohol
por: Matsuura, Tomoka, et al.
Publicado: (2020)

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
por: Al Ashgar, Hamad, et al.
Publicado: (2017)

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
por: Jang, Byoung Kuk
Publicado: (2020)

The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy
por: Hu, Xiaoxia, et al.
Publicado: (2023)

Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
por: Nagura, Yoshihito, et al.
Publicado: (2022)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
por: Tamaki, Nobuharu, et al.
Publicado: (2019)

Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma
por: Suoh, Maito, et al.
Publicado: (2020)

A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation
por: Nishikawa, Hiroki, et al.
Publicado: (2016)

Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are associated with chronic hepatitis C-related hepatocellular carcinoma
por: Hai, Hoang, et al.
Publicado: (2017)

High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use
por: Tamori, Akihiro, et al.
Publicado: (2020)

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy
por: Cao, Weihua, et al.
Publicado: (2021)

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B
por: He, Yi, et al.
Publicado: (2022)

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C
por: Takemura, Kazuya, et al.
Publicado: (2020)

Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir
por: Nishikawa, Hiroki, et al.
Publicado: (2017)

Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed
por: Yoshida, Kanako, et al.
Publicado: (2017)

Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
por: Huang, Yongfa, et al.
Publicado: (2022)

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection
por: Li, Pengpeng, et al.
Publicado: (2023)

Comparison of Hepatocellular Carcinoma miRNA Expression Profiling as Evaluated by Next Generation Sequencing and Microarray
por: Murakami, Yoshiki, et al.
Publicado: (2014)

The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases
por: Fujii, Hideki, et al.
Publicado: (2021)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_srjbt0pjstcdpkac3u4i1suc0l